KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Ginkgo Bioworks Holdings (DNA) over the last 7 years, with Q3 2025 value amounting to $111.1 million.

  • Ginkgo Bioworks Holdings' Cash & Equivalents fell 8197.62% to $111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.1 million, marking a year-over-year decrease of 8197.62%. This contributed to the annual value of $561.6 million for FY2024, which is 4051.6% down from last year.
  • Latest data reveals that Ginkgo Bioworks Holdings reported Cash & Equivalents of $111.1 million as of Q3 2025, which was down 8197.62% from $203.6 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' Cash & Equivalents' 5-year high stood at $1.7 billion during Q3 2021, with a 5-year trough of $111.1 million in Q3 2025.
  • Its 5-year average for Cash & Equivalents is $894.9 million, with a median of $944.1 million in 2023.
  • In the last 5 years, Ginkgo Bioworks Holdings' Cash & Equivalents skyrocketed by 48380.37% in 2022 and then tumbled by 8197.62% in 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Cash & Equivalents (Quarter) stood at $1.6 billion in 2021, then dropped by 15.11% to $1.3 billion in 2022, then fell by 28.25% to $944.1 million in 2023, then tumbled by 40.52% to $561.6 million in 2024, then tumbled by 80.22% to $111.1 million in 2025.
  • Its Cash & Equivalents was $111.1 million in Q3 2025, compared to $203.6 million in Q2 2025 and $312.4 million in Q1 2025.